Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leflunomide is an immunosuppressive disease-modifying antirheumatic drug (DMARD) primarily used to treat moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It works by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which is essential for de novo pyrimidine synthesis required for DNA and RNA production in rapidly dividing cells such as activated lymphocytes. By blocking DHODH, leflunomide reduces the proliferation of these immune cells, thereby decreasing inflammation and slowing disease progression. Its active metabolite, teriflunomide, also inhibits several tyrosine kinases involved in cell signaling pathways related to immune activation[1][5][6][8]. Leflunomide does not cure rheumatoid arthritis but helps control symptoms and improve physical function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leflunomide.